



ASX ANNOUNCEMENT

12 November 2024

## AGM Presentation and CEO Appointment

**Sydney, Australia, 12 November 2024:** Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide the presentation to delivered at the Annual General Meeting to be held today.

**When:** 11:00 am AEDT, 12 November 2024

**Where:** Level 3, 62 Lygon Street, Carlton, Victoria 3053

**Virtual:** <https://web.lumiagm.com/323-551-853>

The presentation includes the appointment of Dr Rebecca McQualter as Chief Executive Officer effective today, and information under Listing Rule 3.16.4.

### ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with

For personal use only



solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

## **CONTACT**

### Investors

Dr Rebecca McQualter  
Chief Operating Officer  
Chimeric Therapeutics  
T: +61 498 966 180  
E: [RMcQualter@chimerictherapeutics.com](mailto:RMcQualter@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For personal use only



CHIMERIC THERAPEUTICS

20  
24

# CHIMERIC

PIONEERS IN CELL THERAPY

Investor Update | 2024

ASX:  
**CHM**

## DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that

applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.





## Dr Rebecca McQualter Appointed Chief Executive Officer



The Company is pleased to announce the appointment of current Chief Operating Officer, Dr Rebecca McQualter as Chief Executive Officer effective from 12 Nov 2024

For the purpose of ASX Listing Rule 3.16.4

Total Fixed Remuneration is A\$350,000 per annum, excluding statutory superannuation effective from 12 Nov 2024

All other terms of the employment agreement remain unchanged as previously disclosed in the Company's Annual Report for the year ended 30 June 2024 released on 21 October 2024.



CHIMERIC THERAPEUTICS

20  
24

# CHIMERIC

PIONEERS IN CELL THERAPY

Investor Update | 2024

ASX:  
**CHM**



For personal use only


CHIMERIC THERAPEUTICS

● ASX:CHM

**CHM is a cancer cell therapy company with 3 CAR T & NK cell assets in 4 Phase 1/1b clinical trials**

# CAR-T CELL THERAPY EXPLAINED

Use a patient's own blood cells to make their individualised cancer therapy



Cell Therapy has been used for over 10 years in patients globally, with great success



Emily Whitehead more than a decade after first CAR-T treatment for blood cancer





# CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

For personal use only  
CHIMERIC THERAPEUTICS



## CHM CDH17

Technology from:



**PHASE 1/2 TRIAL OPEN**  
Sarah Cannon Cancer Centre  
UPenn Oncology



## CHM CLTX

Technology from:



Phase 1A completed: COH

**PHASE 1B TRIAL OPEN**  
Sarah Cannon Cancer Centre



## CHM CORE-NK

Technology from:



<b>PHASE 1B TRIAL OPEN</b> MD Anderson	<b>PHASE 1B TRIAL OPEN</b> Case Western
---	--

# CHM CORE NK + SOC

Ongoing Complete response in high risk blood cancer 48 months durability

## PATIENT #8

33-year-old female

SITE: MDACC

DIAGNOSIS: Myeloid Dysplastic Syndrome

HISTORY: Progressive disease with prior allogeneic transplant

SAFETY: No dose limiting toxicities, no cytokine release syndrome, no GvHD

### CORE NK INFUSION

Patient Doses

### COMPLETE RESPONSE

DAY 100

Enabling patient to undergo transplant


### STABLE DISEASE

DAY 28

### ONGOING COMPLETE RESPONSE

48+ MONTHS

CR = no signs of cancer in response to treatment



For personal use only  
CHIMERIC THERAPEUTICS



# CHM CORE NK COMBINATION TRIAL

Complete response in high risk blood cancer combination trial

**PATIENT #3**  
female

SITE: Case Western

**DIAGNOSIS:** Actue Myeloid  
Dysplastic Syndrome

**SAFETY:** No dose limiting  
toxicities, no cytokine  
release syndrome, no GvHD

CORE NK  
INFUSION + TGF-B

Day 1

**COMPLETE  
RESPONSE**

DAY 28

CR = no signs of cancer  
in response to treatment



# MULTIPLE CLINICAL CATALYSTS IN THE NEXT 12MTHS

## 2023 Achievements and Deliverables in 2024

### 2023 Achievements

### 2024 Deliverables

#### CHM CDH17

- ✓ FDA IND Clearance for Ph. 1/2 Trial

- ✓ Ph. 1/2 Site Open
- ✓ 1st patient dosed
- 1st dose co-hort complete

#### CHM CLTX

- ✓ Ph. 1A trail complete in GBM
- ✓ Ph. 1A Positive Preliminary Data in GBM
- ✓ Ph. 1B 1st Patient Treated in GBM

- Ph. 1B new trial design
- Ph. 1B new trial implemented

#### CHM CORE-NK

- ✓ Ph. 1B ADVENT AML Site Initiation
- ✓ Ph. 1B CORE-NK 0201 + Vactosertib  
1st Patient Treated

- ✓ Ph. 1B ADVENT AML 1st Patient Treated
- ✓ Ph. 1B ADVENT AML Dose Escalation
- Ph. 1B ADVENT AML Frontline
- Ph. 1B Advent AML Preliminary data



# CHM LEADERSHIP TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION



Dr Rebecca McQUALTER  
Chief Executive Officer



Dr Jason LITTEN  
Chief Medical Officer



Dr Stephanie ASTROW  
Chief Scientific Officer



Mr Kelly THORNBURG  
VP Manufacturing

EXPERIENCE **75+** Years of Cell Therapy Experience

EXPERTISE **50+** Development Programs

RESULTS **5/6** FDA-Approved CAR T Cell Therapies





## INVESTMENT HIGHLIGHTS

4

**4 Phase 1 clinical trials**  
under 3 FDA INDs at 4 leading US centres



**Multiple clinical updates**  
in the next 12mths



**Experienced leadership team**  
in cell therapy clinical development



CHM-CDH17  
the **ONLY CDH17 CAR-T** in clinical trials



**First in class**  
CLTX-CAR for brain cancer



**Robust and long life**  
patent portfolio

## CORPORATE PROFILE

Exchange	<b>ASX: CHM</b>
Share Price	<b>\$0.01</b>
52 Week Range	<b>\$0.011- 0.047</b>
Market Cap	<b>~\$10M</b>
Shares on issue	<b>841M</b>

### IPO 2022

Major Shareholder Paul Hopper 10.5%

Effective 11.11.2024



CHIMERIC THERAPEUTICS

20  
24

# CHIMERIC

PIONEERS IN CELL THERAPY

Dr Rebecca McQualter  
Chief Executive Officer  
Chimeric Therapeutics Ltd  
Melbourne, Australia  
Tel: +61 498 966 180  
[investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)